Barclays Lowers Kenvue (NYSE:KVUE) Price Target to $22.00

Kenvue (NYSE:KVUE) had its price objective reduced by equities research analysts at Barclays from $23.00 to $22.00 in a research note issued on Monday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s target price suggests a potential downside of 2.78% from the stock’s current price.

Other research analysts have also issued reports about the company. Citigroup reduced their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Evercore ISI started coverage on shares of Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price for the company. UBS Group lowered their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Redburn Atlantic initiated coverage on shares of Kenvue in a research note on Thursday. They set a “neutral” rating and a $23.50 price objective for the company. Finally, Piper Sandler increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus price target of $24.35.

Kenvue Stock Up 2.4 %

NYSE:KVUE traded up $0.54 during mid-day trading on Monday, reaching $22.63. The company’s stock had a trading volume of 1,125,844 shares, compared to its average volume of 15,085,433. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a fifty day moving average of $22.65 and a 200-day moving average of $22.40. The firm has a market capitalization of $43.25 billion, a PE ratio of 42.70, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities research analysts forecast that Kenvue will post 1.14 earnings per share for the current year.

Institutional Investors Weigh In On Kenvue

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD increased its stake in shares of Kenvue by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company’s stock worth $5,249,665,000 after acquiring an additional 8,211,748 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock valued at $4,665,908,000 after purchasing an additional 1,636,741 shares during the period. Massachusetts Financial Services Co. MA increased its position in Kenvue by 12.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock worth $2,085,070,000 after purchasing an additional 10,682,003 shares during the last quarter. Geode Capital Management LLC raised its stake in Kenvue by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company’s stock worth $980,989,000 after purchasing an additional 1,391,854 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock valued at $912,059,000 after buying an additional 16,269,721 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.